ERLEADA® for Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)

In the SPARTAN study in patients with nmCRPC:

ERLEADA® + ADT improved median metastasis-free survival (MFS) by YEARS (24.3 months) vs placebo + ADT1

(40.5 months vs 16.2 months; HR=0.28; 95% CI: 0.23, 0.35; P<0.0001)

SPARTAN Primary Publication

Review the journal article to learn more about the study results

Accessing this article may require a subscription to The New England Journal of Medicine.


SPARTAN Final Analysis Publication

Review the journal article to learn more about overall survival data in the SPARTAN study

Accessing this article may require a subscription to European Urology.


Exploratory Analysis:

SPARTAN Patient-Reported Outcomes Publication

Review the journal article to learn more about patient-reported outcomes in the SPARTAN study

Accessing this article may require a subscription to The Lancet Oncology.

ADT = androgen deprivation therapy; CI = confidence interval; HR = hazard ratio; nmCRPC = non-metastatic castration-resistant prostate cancer; SPARTAN = Selective Prostate Androgen Receptor Targeting with ARN-509.

Reference

1. ERLEADA® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.